DOUBLE MARKER TEST

Hypro Diagnostics, also known as the double marker test, plays a crucial role in early prenatal screening by evaluating the risk of chromosomal abnormalities, specifically Down’s syndrome, during the first trimester of pregnancy. This screening entails the analysis of maternal serum to identify the levels of beta-human Chorionic Gonadotropin (hCG) and Pregnancy-Associated Plasma Protein-A (PAPP-A), providing valuable insights into fetal development. It is especially recommended for expectant mothers aged 35 and above, given the higher risk associated with advanced maternal age. When coupled with assessments like the nuchal translucency (NT) test, Hypro Diagnostics offers a comprehensive approach to understanding potential genetic risks. This proactive diagnostic tool empowers healthcare providers to deliver tailored guidance and support to pregnant individuals based on a thorough assessment of their unique pregnancy profile.